Full Breakdown
Sharon Stone Describes Withdrawal-Like Illness After Stopping Stroke Medication and Marijuana
7/22/2026, 1:21:22 PM
Core Event
The 68-year-old actress, who survived a near-fatal stroke in 2001, announced that she discontinued one of the prescription drugs prescribed for her stroke recovery last September. Despite medical advice that the medication should not be stopped, Stone persisted and experienced a prolonged period of illness that she likened to “kicking heroin.” She reported feeling “sick as a dog” for roughly four and a half months while attempting to become completely drug-free.
Background & Context
Following the 2001 stroke, Stone was placed on a regimen of several medications to manage neurological damage and prevent further complications. Over the ensuing years she gradually reduced her drug use, eventually deciding to quit both the prescribed medication and recreational marijuana. Stone noted that modern cannabis products contain higher concentrations of THC and additional chemicals, making cessation more difficult than in earlier decades.
Health Impact and Professional Reactions
Stone’s neurologist corroborated her concerns, warning that emergency rooms have seen patients presenting with severe reactions to contemporary marijuana use. The physician emphasized the heightened risk associated with the potency of today’s cannabis products. Medical professionals had previously cautioned Stone that abrupt discontinuation of her stroke medication could jeopardize her recovery, a warning she chose to ignore.
Current Status
After enduring the month-long illness, Stone has returned to acting, appearing in the third season of the television series *Euphoria*. She described the experience as a step toward “reclaiming her life” after years of health challenges.
Outlook
Stone’s public remarks underscore growing anxieties about the health effects of potent marijuana formulations and the dangers of unsupervised medication withdrawal. While she has not announced any further health-related plans, her statements may prompt additional dialogue among patients, physicians, and policymakers regarding safe cessation practices for both prescription drugs and recreational cannabis.
